Secondary Hyperparathyroidism — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for secondary hyperparathyroidism. 24 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
24
Active US patents
45/100
Avg vulnerability
—
Annual revenue covered

Originators in Secondary Hyperparathyroidism

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Kai Pharms Inc 24 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating secondary hyperparathyroidism. Each bar = one year. Y-axis scaled to peak year (12 patents).

9
30
3
31
12
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Parsabiv
ETELCALCETIDE
 Kai Pharms Inc 24 45 — 2030-07-29

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11959486 Parsabiv method of use 75 2034-06-27
11959486 Parsabiv method of use 75 2034-06-27
11959486 Parsabiv method of use 75 2034-06-27
9701712 Parsabiv method of use 68 2030-07-29
9701712 Parsabiv method of use 68 2030-07-29
9701712 Parsabiv method of use 68 2030-07-29
8999932 Parsabiv method of use 68 2031-02-07
8999932 Parsabiv method of use 68 2031-02-07
8999932 Parsabiv method of use 68 2031-02-07
11162500 Parsabiv formulation 42 2034-06-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8377880 Parsabiv composition of matter 10 2030-07-29
9278995 Parsabiv composition of matter 10 2030-07-29
9278995 Parsabiv composition of matter 10 2030-07-29
8377880 Parsabiv composition of matter 10 2030-07-29
8377880 Parsabiv composition of matter 10 2030-07-29
9278995 Parsabiv composition of matter 10 2030-07-29
11162500 Parsabiv formulation 42 2034-06-27
10344765 Parsabiv formulation 42 2034-06-27
10344765 Parsabiv formulation 42 2034-06-27
9820938 Parsabiv formulation 42 2034-06-27

Related